Watch for FDA feedback on the Phase 3 protocol and data readouts from the AASLD presentations in November 2026. Positive regulatory engagement could accelerate belapectin's path to approval.
Price Chart
Executive Summary
Galectin Therapeutics announced it submitted a registrational Phase 3 protocol for belapectin (MASH cirrhosis/portal hypertension) to the FDA and will present three analyses from the NAVIGATE and GT-026 trials at the AASLD Liver Meeting 2026. This is a key milestone moving belapectin toward a pivotal trial, with no approved treatments currently available for this patient population.
Key Facts
- Registrational Phase 3 protocol for belapectin submitted to FDA for MASH cirrhosis and portal hypertension.
- Three presentations at AASLD Liver Meeting 2026 (Nov 5-9, Denver), including an oral presentation and a Poster of Distinction.
- Belapectin has Fast Track designation from FDA.
- No approved treatment options exist for patients with MASH cirrhosis and portal hypertension.
- This is the fourth consecutive major liver meeting where Galectin has been selected for an oral presentation.
Financial Impact
No financial figures stated; milestone-driven event with potential to unlock a large market (MASH cirrhosis with portal hypertension).
Risk Factors
- FDA may request changes to the Phase 3 protocol, delaying trial initiation.
- Phase 3 trial results may not replicate NAVIGATE/GT-026 findings.
- Company has incurred operating losses since inception and may need additional capital to fund the Phase 3 trial.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.38 (−8.40%) |
Oct 13, 2026 14d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.38 (+8.40%) |
Oct 6, 2026 21d ago | Press Release | $3.76 | awaiting T+20 | — | $3.38 (−10.11%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.38 (−1.74%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.38 (−1.74%) |
Aug 4, 2026 12w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.38 (+13.04%) |
Jun 30, 2026 16w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.38 (−21.94%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.38 (+55.76%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.38 (+55.76%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.38 (+43.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers